Invention Grant
- Patent Title: Piperidine derivatives as liver X receptor beta agonists, compositions, and their use
-
Application No.: US16341591Application Date: 2017-10-09
-
Publication No.: US10894775B2Publication Date: 2021-01-19
- Inventor: Michael T. Rudd , Zhaoyang Meng , Jenny Wai , David Jonathan Bennett , Edward J. Brnardic , Nigel J. Liverton , Shawn J. Stachel , Yongxin Han , Paul Tempest , Jiuxiang Zhu , Xuewang Xu , Bin Zhu , Chuanman Huang
- Applicant: Merck Sharp & Dohme Corp. , Michael T. Rudd , Zhaoyang Meng , Jenny Wai , David Jonathan Bennett , Edward J. Brnardic , Nigel J. Liverton , Shawn J. Stachel , Yongxin Han , Paul Tempest , Jiuxiang Zhu , Xuewang Xu , Bin Zhu , Chuanman Huang
- Applicant Address: US NJ Rahway; US PA Collegeville; US PA Ambler; US PA Harleysville; US MA Winchester; US PA Lansdale; US PA Harleysville; US PA Perkasie; US MA Needham; TW Taipei; CN Shanghai; CN Shanghai; CN Shanghai; CN Shanghai
- Assignee: Merck Sharp & Dohme Corp.,Michael T. Rudd,Zhaoyang Meng,Jenny Wai,David Jonathan Bennett,Edward J. Brnardic,Nigel J. Liverton,Shawn J. Stachel,Yongxin Han,Paul Tempest,Jiuxiang Zhu,Xuewang Xu,Bin Zhu,Chuanman Huang
- Current Assignee: Merck Sharp & Dohme Corp.,Michael T. Rudd,Zhaoyang Meng,Jenny Wai,David Jonathan Bennett,Edward J. Brnardic,Nigel J. Liverton,Shawn J. Stachel,Yongxin Han,Paul Tempest,Jiuxiang Zhu,Xuewang Xu,Bin Zhu,Chuanman Huang
- Current Assignee Address: US NJ Rahway; US PA Collegeville; US PA Ambler; US PA Harleysville; US MA Winchester; US PA Lansdale; US PA Harleysville; US PA Perkasie; US MA Needham; TW Taipei; CN Shanghai; CN Shanghai; CN Shanghai; CN Shanghai
- Agent Sylvia A. Ayler; Catherine D. Fitch
- Priority: WOPCT/CN2016/102097 20161014
- International Application: PCT/US2017/055688 WO 20171009
- International Announcement: WO2018/071315 WO 20180419
- Main IPC: C07D221/20
- IPC: C07D221/20 ; C07D211/16 ; C07D211/96

Abstract:
In its many embodiments, the present invention provides certain piperidine compounds of the Formula (I): and pharmaceutically acceptable salts thereof, wherein X, Y, R1, R2, R3, L, R4, L1, Q, and R5 are as defined herein. The novel compounds of the invention, and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X-β receptor (LXRβ) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.
Information query